Search

Your search keyword '"DeMicco, David A."' showing total 345 results

Search Constraints

Start Over You searched for: Author "DeMicco, David A." Remove constraint Author: "DeMicco, David A."
345 results on '"DeMicco, David A."'

Search Results

1. Generic Tagging for RISC-V Binaries

2. Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials

3. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)

4. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus

5. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events

6. Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin

7. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk

8. Abstract 12482: Practical Adherence to AHA/ACC 2018 Guidelines Among Secondary Prevention Patients

9. Body-Weight Fluctuations and Outcomes in Coronary Disease

10. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)

12. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

13. Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study)

14. Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers

15. Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy Effect of Baseline Risk Factors for Diabetes

16. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).

27. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial

38. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories:The SPARCL Trial

41. Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis

42. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis

43. Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes: An Analysis From the CARDS Trial

44. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

50. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)

Catalog

Books, media, physical & digital resources